(AOF) – Acticor Biotech, a biopharmaceutical company that is developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the launch of a capital increase of approximately 10 million euros through the issue of new ordinary shares. This will finance the continuation of the development plan towards the registration of glenzocimab in the emergency treatment of stroke. The funds raised aim to allow the company to finance its operations at least until the third quarter of 2023.
Mediolanum Farmaceutici, a European industrial specialist in health and historical reference shareholder, reaffirms its confidence, with a subscription commitment of up to 7.1 million euros (including 2.1 million by compensation of receivables) out of a total of subscription commitments from historical shareholders and members of the board of directors of 9.3 million euros (including 4.1 million by compensation of receivables). The issue price of the new shares is 6.80 euros per share.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.